Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma
NCT04435977
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
46
Enrollment
OTHER
Sponsor class
Conditions
Hepatocarcinoma
Interventions
DRUG:
Cabozantinib 60 MG
Sponsor
Istituto Clinico Humanitas